Clinical Trial Summary for BRAF-V600E Thyroid Cancer Treatment

A 2024 clinical study summary from the journal Thyroid details a trial of encorafenib and binimetinib combination therapy. The study involved 22 adult participants with metastatic thyroid cancer harboring the BRAF-V600E mutation. Researchers reported a 54.5% response rate and a 90.9% incidence of possible drug-related side effects.

Use Cases

• Analyze the 54.5% response rate and 90.9% side effect incidence from the trial summary to benchmark drug efficacy and safety.
• Extract key results like the most common adverse event (nausea) from the PDF or MP4 files for side effect profile comparisons.
• Use the clinical trial number (jRCT2011200018) to link this plain language summary with primary data from ClinicalTrials.gov.

Strengths

• Results are derived from a published 2024 study in the Thyroid journal, providing a peer-reviewed source.
• The summary provides specific, quantified outcomes including a 54.5% response rate among 22 participants.
• Includes a direct link to the official clinical trial registration (jRCT2011200018) for verification.

Limitations

• The dataset is a summary (PDF/MP4), not the raw patient-level clinical trial data, limiting analytical depth.
• Small sample size of 22 participants restricts statistical power and generalizability of findings.
• Data is static, representing a single study's results published in April 2024, with no ongoing updates.

Provenance

Source

Publication in the journal 'Thyroid', April 2024.

Collection Method

Plain language summary of a clinical trial's published results.

Time Range

Study period not specified; results published in April 2024.

Freshness

Published in April 2024; summary last updated on the platform in March 2026.

Geography

null